Oramed Pharmaceuticals Inc.
ORMP
$2.12
-$0.05-2.30%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 13.29M | -7.64M | -10.19M | -19.62M | 9.21M |
| Total Depreciation and Amortization | 30.00K | 30.00K | 31.00K | 52.00K | 54.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -14.21M | 5.67M | 8.23M | 10.84M | -9.37M |
| Change in Net Operating Assets | -2.64M | -1.57M | 15.00K | 1.63M | 2.18M |
| Cash from Operations | -3.54M | -3.52M | -1.91M | -7.10M | 2.08M |
| Capital Expenditure | -4.00K | -3.00K | -11.00K | -5.00K | 0.00 |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -54.85M | 23.62M | 15.44M | -34.26M | 94.66M |
| Cash from Investing | -54.85M | 23.62M | 15.42M | -34.26M | 94.66M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | 0.00 | 0.00 | -30.55M |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -371.00K | -- | -1.20M | -1.29M | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -371.00K | -- | -1.20M | -1.29M | -30.55M |
| Foreign Exchange rate Adjustments | 40.00K | -1.00K | -2.00K | 3.00K | -4.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -58.72M | 20.10M | 12.32M | -42.65M | 66.18M |